Former FDA Chief Counsel Joins Plan A™ to Launch Male Birth Control

NEXT Life Sciences has appointed Peter Barton Hutt, former Chief Counsel at the U.S. Food & Drug Administration, to its advisory board as the company advances Plan A™, a first-of-its-kind male contraceptive toward potential FDA approval. Hutt's extensive regulatory expertise comes as the product progresses through clinical pathways following successful trials in Canada and Australia.

During his tenure at the FDA, Hutt established foundational structures for modern healthcare regulation, including medical device legislative policy, the Over-the-Counter drug review system, and food nutrition labeling requirements. He created the framework for FDA Guidance documents to establish informal policy and implemented key safety requirements for medical devices. Hutt remains the only lawyer from private practice elected to the National Academy of Medicine and continues practicing as a partner at Covington & Burling LLP while lecturing on food and drug law at Harvard Law School.

Plan A™ employs a proprietary hydrogel called Vasalgel®, which filters sperm from the vas deferens while allowing fluids to pass. The product is designed to provide contraception for more than 10 years and can be administered in a medical office setting with the option for reversal on demand. The technology has demonstrated 100% success rates in two completed trials conducted in Canada and Australia.

Darlene Walley, PhD, CEO and co-founder of NEXT Life Sciences, indicated that Hutt's experience is instrumental in establishing a pathway for Plan A™ to reach market as early as 2027. The appointment strengthens an advisory board already composed of experts in male contraception, positioning the company to navigate the complex regulatory landscape ahead.

Hutt acknowledged the historical challenges in developing male contraceptive options, noting that while many groups have attempted to create viable solutions for decades, the progress of Plan A™ is "quite encouraging". He added that a male contraceptive "will make a sizable impact on humankind".

The development represents a significant advancement in reproductive healthcare options for men, addressing a gap in contraceptive choices that has persisted despite decades of research efforts. NEXT Life Sciences continues to advance through clinical trials as it works toward bringing the first long-acting, reversible male contraceptive to market.

Click here for the original news story.